Recherche
Tiffany Que wins Best Abstract Award at SOHC 2024 for Pioneering CAR-T cell Research
The Department of Oncology is proud to announce that Tiffany Que, one of our promising young researchers, has been awarded the Best Abstract Award at the 2024 Swiss Oncology and Hematology Congress (SOHC) for her oral presentation in the Experimental Hematology/Oncology category.
Tiffany’s talk, “Potency tuned novel CD70 CAR-T cells with a computationally designed CD27:CD70 binding interface for Acute Myeloid Leukemia,” showcased her important work on CAR-T cell therapies pursued in the Arber Lab. By employing advanced computational protein design in collaboration with the Barth Lab at EPFL, she optimized the CD27-CD70 binding interface, enhancing the potency and specificity of CAR-T cells against acute myeloid leukemia (AML). Her research demonstrated significant efficacy in both in vitro and in vivo preclinical models, addressing a critical need for innovative treatments in this area. A clinical trial using this novel CAR is currently in development at the CHUV for children and adults with AML, with generous philanthropic support by the ISREC Foundation, the Jacqueline de Cérenville Foundation and the Jan Baron Mladota Foundation.
Tiffany earned her Bachelor’s degree in Biomedical Sciences from the National University of Singapore and gained industry experience developing biologics targeting solid tumors. She later obtained a Master’s degree in Medical Immunosciences from the University of Bonn, completing her thesis in Zürich where she focused on direct integration of CRISPR/Cas9 screens with single-cell transcriptomics to identify novel targets for cancer immunotherapy.
Currently in the Arber Lab, Tiffany continues to explore novel engineering techniques to develop improved and universal CAR-T cells for AML to address unmet clinical needs in this field.
Congratulations to Tiffany for this well-deserved recognition!
Read the <<abstract>>
About SOHC
Caroline Arber is Associate Professor at the Faculty of Biology and Medicine and the head of the Targeted immunotherapies for hematologic malignancies Lab – Department of Oncology UNIL-CHUV, Immuno-oncology Division, Hematology Division, and part of the Ludwig Institute for Cancer Research, Lausanne Branch
